AU2023275778A1 — Methods of treating cancer with an mtor inhibitor
Assigned to Revolution Medicines Inc · Expires 2024-12-12 · 1y expired
What this patent protects
The present disclosure relates to methods for the treatment of diseases or disorders (e.g, cancer) with mTOR inhibitors. Specifically, the disclosure relates to methods of treating a subject having a cancer by administering a particular dosage of an mTOR inhibitor. In some embodi…
USPTO Abstract
The present disclosure relates to methods for the treatment of diseases or disorders (e.g, cancer) with mTOR inhibitors. Specifically, the disclosure relates to methods of treating a subject having a cancer by administering a particular dosage of an mTOR inhibitor. In some embodiments this disclosure includes methods for delaying, preventing, or treating acquired resistance to RAS inhibitors using a dosage of an mTOR inhibitor. In some embodiments, this disclosure relates to methods of treating or preventing adverse events associated with administration of an mTOR inhibitor using tacrolimus.
Drugs covered by this patent
- Copiktra (DUVELISIB) · Secura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.